Latest News

PhaseRx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding

SEATTLE, Dec. 11, 2017 -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. PhaseRx intends to continue to manage and operate its business under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of...

Published on .

Medigene Collaborates with RXi Pharmaceuticals to Further Sharpen its Therapeutic T cells

MARLBOROUGH, Mass., Dec. 11, 2017 -- RXi Pharmaceuticals Corporation (NASDAQ: RXII) announced today that it has entered into a research collaboration with Medigene AG (MDG1, Frankfurt, Prime Standard, TecDAX) to explore potential synergies of using RXi's self-delivering RNAi technology (sd-rxRNA®) in combination with Medigene's recombinant TCRs to develop modified T cells with enhanced efficacy and/or safety. The preclinical research program will examine the applicability of RXi's...

Published on .

PacWest Bancorp Announces Loan Portfolio Sale

LOS ANGELES, Dec. 11, 2017 -- PacWest Bancorp (Nasdaq:PACW) (“PacWest”) today announced it has agreed to sell cash flow loans with an aggregate carrying value of $1.49 billion as of November 30, 2017 and expects to recognize a pre-tax gain of approximately $13 million. In connection with the sale of this portfolio, PacWest is exiting its commercial lending origination operations related to Healthcare, Technology and General Cash Flows, while retaining and continuing to grow its Security Cash...

Published on .

Alimera Sciences Announces Patients Now Being Treated With ILUVIEN® In Ireland

ATLANTA, Dec. 11, 2017 -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that the first patients in Ireland were treated with ILUVIEN®, its sustained release intravitreal implant for the treatment of diabetic macular edema (DME).“The availability of ILUVIEN in Ireland is good news for patients and retina specialists alike,” said Mr. David Kent M.D., Consultant Ophthalmic Surgeon &...

Published on .

Interim Report Q1-Q3 2017/18, Strategic focus changed, Asset sales to be accelerated, Profit guidance lowered, Change of management

Company announcement no. 9/2017SummarySTRATEGIC FOCUS CHANGED, ASSET SALES TO BE ACCELERATED AND PROFIT GUIDANCE LOWEREDThe Board of Directors has today resolved that TK Development will change its strategic focus. Going forward, focus will be on the Danish and Swedish property development business, while efforts will be made to divest the Group’s Polish activities within a period of two years.The Group’s previous asset management activities will be divested sooner than originally planned.Due...

Published on .

Integra LifeSciences Hosts Investor Day 2017 New York City

PLAINSBORO, N.J., Dec. 11, 2017 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today will host an Investor Day meeting with analysts and institutional investors in New York City, beginning at 8:00 a.m. EST. Members of Integra’s executive leadership team will discuss the company’s financial performance and outlook.Highlights of today’s conference include:•  Reaffirming 2017 financial guidance as provided on October 26, 2017, including:Full-year...

Published on .

ADMA Files Biologics License Application For Its Third Plasma Collection Center

RAMSEY, N.J. and MARIETTA, Ga., Dec. 11, 2017 -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease (“PIDD”) and the prevention and treatment of certain infectious diseases, announces the filing of a Biologics License Application (“BLA”) for its third plasma collection center located...

Published on .

Hamilton Lane Again Recognized by both Pensions & Investments and Central Penn Business Journal as a ‘Best Place to Work’

BALA CYNWYD, Pa., Dec. 11, 2017 -- Hamilton Lane (NASDAQ:HLNE) has been named to Pensions & Investments’ “Best Places to Work in Money Management” list for 2017. Hamilton Lane is one of only five companies to have been included on the list for six consecutive years, since Pensions & Investments first began publishing the rankings in 2012.Additionally, the Bala Cynwyd, Penn.-headquartered firm ranked in the top quartile of companies on the “Best Places to Work in PA” list...

Published on .

Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs

Conference Call and Webcast Today at 4:30 p.m. ETNEW YORK, Dec. 11, 2017 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the fiscal year ended September 30, 2017.The...

Published on .

Preclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented at 28th International Symposium on ALS/MND

CAMBRIDGE, Mass., Dec. 11, 2017 -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced data from preclinical studies of WVE-3972-01, the company’s investigational stereopure antisense oligonucleotide designed to target the pathogenic allele of the C9ORF72 gene for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). In preclinical...

Published on .